PRA Health Sciences (PRAH) Tops Q4 EPS by 7c

PRA Health Sciences (NASDAQ: PRAH) reported Q4 EPS of $0.71, $0.07 better than the analyst estimate of $0.64. Revenue for the quarter came in at $413.6 million versus the consensus estimate of $405.04 million.

GUIDANCE:

PRA Health Sciences sees FY2017 Adj. EPS of $3.08-$3.18, versus the consensus of $2.96.

For earnings history and earnings-related data on PRA Health Sciences (PRAH) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• DA Davidson Reiterates Buy Rating on Boost Run (BRUN)
• Benchmark Reiterates Buy Rating on Odysight.AI Inc. (ODYS)